CDX 1401

Drug Profile

CDX 1401

Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Gynaecological cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 03 Dec 2016 Accrued efficacy data from a phase I trial in Myelodysplastic syndromes and Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 29 Jul 2016 Case Comprehensive Cancer Center plans a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (NCT02661100)
  • 04 Jun 2016 Adverse events data from a phase II trial in Malignant melanoma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO- 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top